Capital Guardian Trust Co. decreased its stake in shares of AstraZeneca plc (NYSE:AZN) by 40.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 107,520 shares of the company’s stock after selling 71,880 shares during the period. Capital Guardian Trust Co.’s holdings in AstraZeneca were worth $3,643,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Trexquant Investment LP bought a new position in AstraZeneca in the second quarter valued at $450,000. Pinnacle Financial Partners Inc. grew its position in AstraZeneca by 2.5% in the second quarter. Pinnacle Financial Partners Inc. now owns 9,233 shares of the company’s stock valued at $314,000 after purchasing an additional 229 shares in the last quarter. Checchi Capital Advisers LLC grew its position in AstraZeneca by 4.2% in the second quarter. Checchi Capital Advisers LLC now owns 21,012 shares of the company’s stock valued at $716,000 after purchasing an additional 841 shares in the last quarter. SG Americas Securities LLC grew its position in AstraZeneca by 29.8% in the second quarter. SG Americas Securities LLC now owns 25,919 shares of the company’s stock valued at $884,000 after purchasing an additional 5,956 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in AstraZeneca by 6.1% in the second quarter. Bank of New York Mellon Corp now owns 195,965 shares of the company’s stock valued at $6,681,000 after purchasing an additional 11,311 shares in the last quarter. 14.75% of the stock is owned by institutional investors.

A number of research analysts recently weighed in on the stock. Liberum Capital downgraded shares of AstraZeneca from a “buy” rating to a “hold” rating in a research report on Thursday, September 14th. BNP Paribas raised shares of AstraZeneca from a “neutral” rating to an “outperform” rating in a research report on Monday, September 25th. BMO Capital Markets reaffirmed a “buy” rating and issued a $38.00 target price on shares of AstraZeneca in a research report on Tuesday, November 7th. Citigroup raised shares of AstraZeneca to a “buy” rating in a research report on Wednesday, October 18th. Finally, Sanford C. Bernstein raised shares of AstraZeneca from a “market perform” rating to an “outperform” rating and raised their target price for the company from $30.00 to $39.00 in a research report on Friday, September 22nd. Four analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $34.20.

Shares of AstraZeneca plc (NYSE AZN) opened at $33.12 on Tuesday. The company has a market cap of $82,896.44, a price-to-earnings ratio of 7.81, a price-to-earnings-growth ratio of 2.98 and a beta of 0.72. The company has a debt-to-equity ratio of 1.09, a current ratio of 0.94 and a quick ratio of 0.72. AstraZeneca plc has a 12 month low of $26.51 and a 12 month high of $35.60.

AstraZeneca (NYSE:AZN) last announced its quarterly earnings results on Thursday, November 9th. The company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.55. The firm had revenue of $6.23 billion during the quarter, compared to analysts’ expectations of $6 billion. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter last year, the company posted $1.32 earnings per share. equities research analysts expect that AstraZeneca plc will post 1.87 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Capital Guardian Trust Co. Lowers Stake in AstraZeneca plc (AZN)” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/12/12/capital-guardian-trust-co-lowers-stake-in-astrazeneca-plc-azn.html.

AstraZeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.